← Leaderboards
Ognjen Gajic
Mayo Clinic
$8,004,701
Attributed
$21,486,104
Total exposure
8
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.4M · FY2005–25$2.5M$1.9M$1.3M$625K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$21,486,104 · 8
By mechanism
UH3$11,052,938 · 2
U01$6,066,972 · 1
UG3$1,419,180 · 1
RC1$931,419 · 1
R61$783,661 · 1
K23$620,375 · 1
Top collaborators
- Michelle Ng Gong10 shared
- Emir Festic5 shared
- Joseph Eric Levitt5 shared
- Kenneth W. Mahaffey5 shared
- Michael A. Matthay5 shared
- Daniel Stuart Talmor5 shared
Others in their field
Top investigators on “Clinical Trials”
- Lawrence Corey · Fred Hutchinson Cancer Center$824,102,536
- Sonia M Thomas · Research Triangle Institute$700,865,642
- David Heimbrook · Leidos Biomedical Research, Inc.$622,583,125
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$542,008,718
- Bambra Strokes · Ppd Development Lp$526,656,217
- Judith S. Currier · University Of California Los Angeles$504,273,077
Research focus
Clinical TrialsPreventionLung InjuryAcuteMechanical VentilationUnited StatesCritical CareHigh RiskInjuryLength Of StayEtiologyCritical IllnessPreventAdult Respiratory Distress SyndromeHourResearch InfrastructureFutureMedicineAcute Respiratory FailureEventAdmission ActivityBaseEnrollmentCost
Grant awards (22)
Pragmatic trial of midodrine as a vasopressor-sparing agent in septic shock$783,661
R61 · FY2025 · HL · contact PI
1/1: ARREST RESPIRATORY FAILURE DUE TO PNEUMONIA (ARREST PNEUMONIA)$1,581,887
UH3 · FY2023 · HL
1/1: ARREST RESPIRATORY FAILURE DUE TO PNEUMONIA (ARREST PNEUMONIA)$2,068,764
UH3 · FY2022 · HL
1/1: ARREST RESPIRATORY FAILURE DUE TO PNEUMONIA (ARREST PNEUMONIA)$2,064,826
UH3 · FY2021 · HL
1/1: ARREST RESPIRATORY FAILURE DUE TO PNEUMONIA (ARREST PNEUMONIA)$2,065,518
UH3 · FY2020 · HL
1/1: ARREST RESPIRATORY FAILURE DUE TO PNEUMONIA (ARREST PNEUMONIA)$1,419,180
UG3 · FY2019 · HL
Prevention of Severe Acute Respiratory Failure in Patients with PROOFCheck - an E$653,512
UH3 · FY2018 · HL
Prevention of Severe Acute Respiratory Failure in Patients with PROOFCheck - an E$167,115
UH3 · FY2018 · HL
Prevention of Severe Acute Respiratory Failure in Patients with PROOFCheck - an E$820,627
UH3 · FY2017 · HL
Prevention of Severe Acute Respiratory Failure in Patients with PROOFCheck - an E$821,506
UH3 · FY2016 · HL
Prevention of Severe Acute Respiratory Failure in Patients with PROOFCheck - an E$457,591
UH3 · FY2015 · HL
Prevention of Severe Acute Respiratory Failure in Patients with PROOFCheck - an E$351,592
UH3 · FY2015 · HL
Prevention of Severe Acute Respiratory Failure in Patients with PROOFCheck - an E$611,559
UH2 · FY2014 · HL
LIPS-A: Lung Injury Prevention Study with Aspirin$2,217,606
U01 · FY2013 · HL · contact PI
LIPS-A: Lung Injury Prevention Study with Aspirin$2,384,003
U01 · FY2012 · HL · contact PI
LIPS-A: Lung Injury Prevention Study with Aspirin$1,465,363
U01 · FY2011 · HL · contact PI
In Silico Model for Acute Lung Injury Prediction and Clinical Trial Design$931,419
RC1 · FY2010 · LM · contact PI
Transfusion Related Lung Injury in the Critically Ill$123,994
K23 · FY2009 · HL · contact PI
Transfusion Related Lung Injury in the Critically Ill$124,409
K23 · FY2008 · HL · contact PI
Transfusion Related Lung Injury in the Critically Ill$123,706
K23 · FY2007 · HL · contact PI
Transfusion Related Lung Injury in the Critically Ill$123,025
K23 · FY2006 · HL · contact PI
Transfusion Related Lung Injury in the Critically Ill$125,241
K23 · FY2005 · HL